The global narcolepsy therapeutics market was valued at USD 3.28 billion in 2022. Projections indicate a rise to USD 6.01 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 7.85% from 2023 to 2030.
Narcolepsy is a chronic sleep disorder characterized by sudden, irresistible sleep attacks, significantly impacting a patient's daily life. Several factors are fueling the market's expansion, including the increasing incidence of the disease, a surge in research and development (R&D) activities and investments, and the introduction of innovative therapeutic products. The National Institute of Neurological Disorders and Stroke (NINDS) estimates that between 135,000 and 200,000 individuals in the U.S. are affected by narcolepsy. The disease's prevalence is expected to climb in the coming years due to rising stress levels contributing to its onset.
Increased R&D efforts aimed at developing novel treatments for narcolepsy are a significant market driver. These activities have accelerated in recent years, promising new treatment options. For example, in May 2021, Takeda Pharmaceutical Company Limited initiated R&D for narcolepsy drug candidates, with an anticipated market approval application by March 2025. Furthermore, the availability of recently approved medications is boosting the prescription of new drugs, offering improved treatment choices. An instance of this is the U.S. FDA's approval of Xywav in July 2020 for the treatment of narcolepsy in patients aged seven years and older.
Key Market Insights:
- North America led the narcolepsy therapeutics market in terms of revenue in 2022, capturing a 38.03% share. This dominance is attributed to increased R&D activities and effective collaborations among research institutions, academic bodies, and the corporate sector within the region.
- By treatment type, Narcolepsy with Cataplexy was the largest segment by revenue in 2022, holding a 54.28% market share. This is due to the growing prevalence of cataplexy as a primary symptom in narcolepsy patients and the increasing adoption of novel medications like WAKIX, Xyrem, and Xywav for its treatment.
- In terms of product, the Sodium Oxybate segment dominated the market in 2022 with a revenue share of 46.70% and is projected to experience the fastest CAGR during the forecast period. High prescription rates, the substantial cost of these drugs, the presence of favorable reimbursement policies, and rising awareness regarding diagnosis and associated treatments are expected to drive the segment's growth.
Order a free sample PDF of the Narcolepsy Therapeutics Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
- 2022 Market Size: USD 3.28 Billion
- 2030 Projected Market Size: USD 6.01 Billion
- CAGR (2023-2030): 7.85%
- North America: Largest market in 2022
- Asia Pacific: Fastest growing market
Key Companies & Market Share Insights
Market participants are actively pursuing strategies such as product launches, acquisitions, and strategic collaborations to strengthen their market presence. For example, in May 2023, Avadel Pharmaceuticals secured final U.S. FDA approval for Lumryz, a treatment for narcolepsy. Likewise, in May 2022, Axsome Therapeutics, Inc. completed the acquisition of Sunosi from Jazz Pharmaceuticals, further expanding its U.S. portfolio. Additionally, several companies are enhancing patient access and boosting market penetration through initiatives like reduced out-of-pocket costs and free product offerings for eligible individuals. Jazz Pharmaceuticals, for instance, has implemented Patient Assistance Programs to support patients lacking sufficient insurance coverage for prescribed therapies.
Key Players
- Teva Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals, Inc.
- Harmony Biosciences
- Novartis AG
- Rhodes Pharmaceuticals L.P.
- Janssen Global Services, LLC
- Eli Lilly and Company
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The narcolepsy therapeutics market is experiencing significant growth, driven by an increasing prevalence of the condition, intensified research and development efforts, and the introduction of new treatments. North America currently leads the market, with narcolepsy with cataplexy being the dominant treatment segment and sodium oxybate as the leading product. Market expansion is further supported by government initiatives, funding, and awareness programs, with major pharmaceutical companies actively expanding their presence through strategic product launches and acquisitions.
